Cereno Scientific obtains first patent in India for drug candidate CS1 through its third patent family
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced that drug candidate CS1’s third patent family has obtained a patent in India. This strengthens and broadens the intellectual property rights (IPR) for Cereno’s Phase II drug candidate CS1, which is being developed for the treatment of rare disease pulmonary arterial hypertension (PAH).“This is the first issued patent in India for our CS1 patent portfolio, which strengthens the drug candidate’s global IPR. India is a major pharmaceutical